Search
ProMIS Neurosciences Inc
PMNAdd to Watchlist
14.010USD
+0.550+4.09%
Close 09-18 16:00（ET）
123.75MMarket Cap
LossP/E TTM
More Details of ProMIS Neurosciences Inc Company
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
ProMIS Neurosciences Inc Profile
Ticker SymbolPMN
Company nameProMIS Neurosciences Inc
IPO dateApr 03, 2017
CEOWarma (Neil K)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endApr 03
AddressSuite 200, 1920 Yonge Street
CityTORONTO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeM4S 3E2
Phone14168476898
Websitehttps://www.promisneurosciences.com/
Ticker SymbolPMN
IPO dateApr 03, 2017
CEOWarma (Neil K)
Company Executives of ProMIS Neurosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Neil Cashman, M.D.
Dr. Neil Cashman, M.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
9.36K
+44.03%
Dr. Neil Cashman, M.D.
Dr. Neil Cashman, M.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
9.36K
+44.03%
Mr. Patrick D. Kirwin
Mr. Patrick D. Kirwin
Independent Director
Independent Director
7.09K
-0.03%
Mr. Patrick D. Kirwin
Mr. Patrick D. Kirwin
Independent Director
Independent Director
7.09K
-0.03%
Dr. Johanne Kaplan, Ph.D.
Dr. Johanne Kaplan, Ph.D.
Chief Development Officer
Chief Development Officer
6.22K
+36.65%
Dr. Johanne Kaplan, Ph.D.
Dr. Johanne Kaplan, Ph.D.
Chief Development Officer
Chief Development Officer
6.22K
+36.65%
Mr. Neil K. Warma
Mr. Neil K. Warma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.18K
--
Mr. Neil K. Warma
Mr. Neil K. Warma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.18K
--
Mr. William Wyman
Mr. William Wyman
Independent Director
Independent Director
--
--
Mr. Eugene W. Williams
Mr. Eugene W. Williams
Chairman of the Board
Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Neil Cashman, M.D.
Dr. Neil Cashman, M.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
9.36K
+44.03%
Dr. Neil Cashman, M.D.
Dr. Neil Cashman, M.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
9.36K
+44.03%
Mr. Patrick D. Kirwin
Mr. Patrick D. Kirwin
Independent Director
Independent Director
7.09K
-0.03%
Mr. Patrick D. Kirwin
Mr. Patrick D. Kirwin
Independent Director
Independent Director
7.09K
-0.03%
Dr. Johanne Kaplan, Ph.D.
Dr. Johanne Kaplan, Ph.D.
Chief Development Officer
Chief Development Officer
6.22K
+36.65%
Dr. Johanne Kaplan, Ph.D.
Dr. Johanne Kaplan, Ph.D.
Chief Development Officer
Chief Development Officer
6.22K
+36.65%
FAQs
Who are the top five shareholders of ProMIS Neurosciences Inc?
The top five shareholders of ProMIS Neurosciences Inc are: Dr. Neil Cashman, M.D.
How many institutions hold shares of ProMIS Neurosciences Inc (PMN)?
As of 2026Q1, 44 institutions hold shares of ProMIS Neurosciences Inc, with a combined market value of approximately 2.50M, accounting for 27.86% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1952220.00.